drugset / Trial / NCT02919449
Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab
NaSingle-groupOpen-labelTreatment
Summary
This a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of attenuated Measles virus (MV-NIS) combined with Atezolizumab in patients with recurrent and metastatic NSCLC.
Timeline
- Start
- 2017-08-03
- Primary completion
- 2018-01-19
- Completion
- 2018-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MV-NIS | Unknown | 1e+08 unknown | Other |
| Background | Atezolizumab | Monoclonal antibody | — | — |